Microbio announces new status as an unlisted Public Company

Queensland’s Microbio has become an unlisted public company in a move to position the biotechnology scale-up for expansion into international markets. This move to public company status coincided with the company’s recent CE Mark of approval for the use of its revolutionary Bloodstream Infection test, Microbio InfectID-BSI in Europe. Read more in the media release:… Continue reading Microbio announces new status as an unlisted Public Company

Microbio’s bloodstream infection test cleared for sale in Europe

Australian biotech scaleup, Microbio is set to break into the European market with its flagship bloodstream infection (BSI) test. Following extensive clinical evaluation trials, the company has been granted a CE Mark, which has opened the door for distribution and use in Europe. Read more in the media release: 220614_Australian_bloodstream_infection_test_cleared_for_sale_in_Europe

Independent assessment of Microbio bloodstream infection test expected to be completed in May

Queensland biotechnology company Microbio expects clinical evaluation trials of its InfectID-BSI tests to be completed next month, prior to launching in the European market. US based Landrich Group is managing the trials at four locations in the USA, South America, India and Australia, undertaking a performance evaluation of Microbio InfectID assays. Read more in the… Continue reading Independent assessment of Microbio bloodstream infection test expected to be completed in May